<DOC>
	<DOCNO>NCT02593123</DOCNO>
	<brief_summary>Determine relapse-free , donor lymphocyte infusion ( DLI ) -free survival patient receive investigational regimen.This randomize phase II clinical trial , compare two different dose schedule mycophyenolate mofetil graft versus host disease ( GVHD ) prevention follow allogeneic stem cell transplantation . Risk relapse , GVHD non-relapse mortality assess . Adaptive randomization two study arm perform base T cell count day 60 .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy : Early GVHD Prophylaxis</brief_title>
	<detailed_description>In study , investigator utilize regimen combine low dose total body irradiation rabbit ATG facilitate stem cell transplantation ( SCT ) HLA match related unrelated donor . Based hypothesis early treatment intervention significant late effect allogeneic SCT , simple intervention , vary duration intense immunosuppression follow SCT , investigate study . This may allow robust recovery donor immune system cell first two month follow transplantation eventually result low risk cancer relapse , maintain effective graft versus host disease ( GVHD ) control . Patients randomly assign receive GVHD prevention therapy use one two different immunosuppressive regimen tacrolimus &amp; mycophenolate mofetil ( MMF ) . Patients assign investigational group receive MMF 15 day follow SCT growth factor support use granulocyte macrophage colony stimulate factor ( GM-CSF ) begin post-transplant day 4 . Patients randomized standard treatment group receive MMF 30 day follow SCT cytokine support use granulocyte colony stimulate factor ( G-CSF ) begin post-transplant day 4 . If one treatment group demonstrate improvement donor immune cell recovery , may slow increase likelihood patient assign successful treatment group . Eventually two group compare respect likelihood either relapse GVHD developing .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion Criteria Any follow high risk recurrent hematological malignancy : Hodgkin lymphoma ( HL ) NonHodgkin lymphoma ( NHL ) Chronic lymphocytic leukemia ( CLL ) Multiple myeloma ( MM ) Acute myelogenous leukemia ( AML ) *Note : Determination malignancy high risk make investigator . Investigator determination patient appropriate candidate reduce intensity allogeneic SCT standard Massey Cancer CenterVirginia Commonwealth Health System Bone Marrow Transplant MCCVCUHS BMT Program regimen employ trial Patients without previous myeloablative autologous transplant HLAmatched stem cell donor , either relate ( 6/6 5/6 locus match ) unrelated ( 8/8 7/8 locus match ) *Note : Unrelated donor must match HLAA , B , C , DRB1 locus . However , single locus mismatch acceptable event closely match donor available . Age â‰¥ 50 &lt; 75 year ; patient 18 49 year age eligible investigator determine patient comorbidity ( y ) preclude conventional allogeneic transplantation full intensity myeloablative conditioning Karnofsky Performance Status 70100 % Negative serology HIV Women postmenopausal undergone hysterectomy must document negative serum pregnancy test per standard MCCVCUHS BMT Program guideline Ability understand willingness sign write informed consent document *Note : The consent form must sign dated prior initiation SCT preparative treatment . Exclusion Criteria Previous therapeutic radiation therapy ( RT ) exceed critical structure tolerance dos determine radiation oncologist Uncontrolled viral , fungal , bacterial infection Active meningeal central nervous system disease Previous therapy rabbit antithymocyte globulin ( ATG ) ; previous treatment equine ATG allow 3 month ago *Note : Previous myeloablative autologous transplant permit require . Pregnancy breastfeed Medical , psychological , social condition , opinion investigator , may increase patient 's risk limit patient 's adherence study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>